The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
The Breakwater study hits on overall survival with "unprecedented" data.
Crunch time approaches for UroGen.
The combined company's MALT1 inhibitor has started phase 1.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.